版本:
中国

BRIEF-Merck receives complete response letter from the FDA for Tecos study with sitagliptin

April 7 Merck & Co Inc

* Merck receives complete response letter from the U.S. FDA for Tecos study with Sitagliptin

* Merck & Co Inc- Merck is reviewing letter and will discuss next steps with FDA

* Merck & Co- with the applications, co seeking to include data from Tecos in prescribing information of Sitagliptin-containing medicines Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐